Outcome for patients who relapse after chemotherapy for stage 4 urothelial carcinoma (UC) is poor. Optimal second-line chemotherapy remains undefined.¹ As such, there is a significant unmet need for therapies that are well tolerated and confer clinical benefit in this population. Recent encouraging data with immune checkpoint inhibitors have resulted in positive randomized phase 3 studies and regulatory approvals.